medicines patent pool

Johnson & Johnson is expected to announce Monday, December 19, whether it intends to license its patents on three lifesaving HIV/AIDS drugs to the Medicines Patent Pool, a mechanism designed to lower prices of HIV medicines and increase access to them for people in the developing world.

Over the past two years, Doctors Without Borders/Médecins Sans Frontières (MSF) has been urging Johnson & Johnson to take this critical step.

Johnson & Johnson has so far refused to join discussions on licensing these patents to the Medicines Patent Pool. The Pool has been set up to increase access to more affordable versions of HIV drugs, including fixed-dose combinations that include multiple medicines in one pill, and to develop much-needed pediatric HIV drugs.

The Pool would license patents on HIV drugs to other manufacturers and the resulting competition would dramatically reduce prices, making them much more affordable in the developing world. However, since the Pool is voluntary it will only work if patent holders like Johnson & Johnson choose to participate.

ACT NOW: Call on Johnson & Johnson to finally join the Medicines Patent Pool

Thank you to everyone for helping us reach our goal of 8,000 emails to tell Johnson & Johnson to stop turning its back on AIDS patients.

Now we’re trying for 9,000+ emails. Keep spreading the word so that by Monday, December 19, when pharmaceutical giant Johnson & Johnson is expected to announce whether it intends to license its patents on three lifesaving HIV/AIDS drugs to the Medicines Patent Pool, a mechanism designed to lower prices of HIV medicines and increase access to them for people in the developing world, they will see a huge response.

youtube

There is a solution to improving HIV treatment and access to that treatment- the Medicines Patent Pool. Here’s how a patent pool could work.

youtube

There are over 2 million HIV positive children in the world, 90 percent of whom are in sub-Saharan Africa and only 10 percent of them have access to treatment. Access, as well as the quality of care, must be improved as must diagnostic tools for early intervention and treatment. Without treatment, one third of children with the virus will die before their first birthday. Half won’t live to see their second birthday.